Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical preparation containing pyridyl aminoacetic acid compound

A pharmaceutical preparation and content technology, which is applied in the field of pharmaceutical preparations for the treatment or prevention of glaucoma or ocular hypertension, and can solve problems such as omipag that is not recorded

Pending Publication Date: 2020-08-11
SANTEN PHARMA CO LTD
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, there is absolutely no description in any literature of what effect omipag or its esters or their salts show on patients whose effects of other glaucoma or ocular hypertension therapeutic drugs are insufficient, and there is also nothing about such an effect Other literature, research reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical preparation containing pyridyl aminoacetic acid compound
  • Pharmaceutical preparation containing pyridyl aminoacetic acid compound
  • Pharmaceutical preparation containing pyridyl aminoacetic acid compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0120] [Preparation example]

[0121] Omeparag or its esters or their salts of the present invention can be used to manufacture pharmaceutical preparations as described above. Representative formulation examples of the pharmaceutical formulation of the present invention are shown below. In addition, in the following formulation examples, the compounding quantity of each component is the content in 100 mL of formulations.

preparation example 1

[0123] Eye drops 1 (in 100mL)

[0124]

preparation example 2

[0126] Eye drops 2 (in 100mL)

[0127]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to discover a pharmaceutical preparation which is for treating or preventing glaucoma or intraocular hypertension and exhibits effects on a patient in which theefficacy of a therapeutic agent for glaucoma or intraocular hypertension is insufficient. It is found that omidenepag, an ester thereof, or a salt thereof is proven to exhibit an excellent intraocular tension depressive action on a patient in which the efficacies of other therapeutic agents for glaucoma or intraocular hypertension are insufficient. Therefore, omidenepag, an ester thereof, or a salt thereof according to the present invention is useful as a pharmaceutical preparation capable of treating or preventing glaucoma or intraocular hypertension even on a patient in which the efficaciesof other therapeutic agents for glaucoma or intraocular hypertension are insufficient.

Description

technical field [0001] The present invention relates to a pharmaceutical preparation for treating or preventing glaucoma or ocular hypertension containing omirpag or an ester thereof or a salt thereof as an active ingredient, the pharmaceutical preparation being administered to other glaucoma or ocular hypertension Patients with insufficient therapeutic effect. Background technique [0002] Glaucoma is a refractory eye disease in which the intraocular pressure increases due to various causes, and the internal tissues (retina, optic nerve, etc.) of the eyeball are damaged, and there is a risk of blindness. As a treatment method for glaucoma, intraocular pressure lowering therapy is generally used, and as a representative treatment method, there are drug therapy, laser therapy, surgery, and the like. [0003] Use of sympathetic agonists (nonselective stimulants such as dipifolin, alpha brimonidine such as 2 agonists), sympathetic blockers (timolol, benfurolol, carteolol, nip...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/444A61K31/5575A61P27/06
CPCA61K31/444A61K31/5575A61P27/06A61K45/06A61K9/0048A61K47/10A61K47/14A61K9/0051A61K2300/00A61P27/00
Inventor 川田久川端敬子N·沙姆斯
Owner SANTEN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com